Haemoglobinopathies in Europe: Health & migration policy perspectives

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Aguilar Martinez, Patricia ^a   Angastiniotis, Michael ^b   Eleftheriou, Androulla ^b   Gulbis, Beatrice ^c   Mañú Pereira, Maria Del Mar ^d   Petrova Benedict, Roumyana ^e   Corrons, Joan Lluis Vives ^d  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b Thalassaemia International Federation   (Cyprus)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d HOSPITAL CLÍNIC   (Spain)

^e INTERNATIONAL ORGANIZATION FOR MIGRATION   (Switzerland)

Author keywords

Europe; Haemoglobinopathies; Migrant health; Policy recommendations; Population migration; Sickle cell disease; Thalassaemia

Indexed keywords

ADULT; BELGIUM; COST CONTROL; CYPRUS; EUROPE; FOLLOW UP; FRANCE; GERMANY; GREECE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEMOGLOBINOPATHY; HUMAN; ITALY; MIGRATION; NETHERLANDS; NEWBORN SCREENING; PREVALENCE; QUALITY OF LIFE; REVIEW; SOCIAL SUPPORT; SPAIN; SWEDEN; UNITED KINGDOM; ANEMIA; ARTICLE; ATTITUDE TO ILLNESS; BONE NECROSIS; CONTROLLED STUDY; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS C; IRON OVERLOAD; MAJOR CLINICAL STUDY; OSTEOPOROSIS; HEMOGLOBINOPATHIES;

HEMOGLOBIN;

EMIGRATION AND IMMIGRATION; EUROPE; HEALTH POLICY; HEMOGLOBINOPATHIES; HUMANS;

EID: 84904316846     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-97     Document Type: Review

References (24)

1. Management of haemoglobin disorders: report of joint WHO-TIF Meeting, Cyprus, November 2007 2007 http://www.who.int/genomics/WHO-TIF-genetics-final. pdf
2. Haemoglobinopathies on the Move, Is Europe ready? Health and Migration Policy Perspectives http://www.enerca.org and http://www.thalassaemia.org.cy
3. Modell B, Darlison M, Global epidemiology of haemoglobin disorders and derived service indicators, Bulletin of the World Health Organization 2008 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2647473/pdf/06-036673.pdf
4. Epidemiology of rare anaemias in Europe. Gulbis B, Eleftheriou A, Angastiniotis M, Ball S, Surrallés J, Castella M, Heimpel H, Hill A, Corrons JL, Adv Exp Med Biol 2010 686 375 396
5. Neonatal haemoglobinopathy screening in Spain. Mañu Pereira M, Vives Corrons JL, J Clin Pathol 2009 62 22 25
6. What Is Sickle Cell Anemia? US National Heart Lung and Blood Institute http://www.nhlbi.nih.gov/health/health-topics/topics/sca/
7. What are thalassemias? US National Heart Lung and Blood Institute http://www.nhlbi.nih.gov/health/health-topics/topics/thalassemia/
8. Survival of medically treated thalassaemia major patients in Cyprus. Trends and risk factors over the period 1980-2004. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M, Haematologica 2006 91 9 1187 1192 (Pubitemid 44408428)
9. The impact of migrations on the health services for rare diseases in Europe: The example of haemoglobin disorders. Angastiniotis M, Vives Corrons JL, Soteriades ES, Eleftheriou A, Sci World J 2013 2013 727905
10. Management of thalassaemia (Chapter 11), R. Galanello, R. Origa, European School of Haematology (ESH) Handbook on Disorders of Erythropoiesis, Erythrocytes and Iron Metabolism, December 2009 2009 http://www.esh.org/files/ doc/IRON2009-CAP.11(264-285).pdf
11. Sickle cell disease: a short guide to management (Chapter 13), F. Galactéros, M. de Montalembert, European School of Haematology (ESH) Handbook on Disorders of Erythropoiesis, Erythrocytes and Iron Metabolism, December 2009 2009 http://www.ironcurriculum.esh.org/Activity/1819-03/1819-03- chapter13.pdf
12. on behalf of the European network for rare and congenital anaemias. De Montalembert M, Ferster A, Colombatti R, Rees DC, Gulbis B, Am J Hematol 2010 34 72 74
13. De Franchesi L, Bachir D, Galacteros F, Gulbis B, Voskaridou E, Ribeiro L, ENERCA Recommendations for first line management and standard follow up of Young and adult patients with sickle cell diseases (SCD) 2012 http://www.enerca.org
14. The WHO Resolution on Migrant Health (WHA 61.17, 2008) 2008 http://apps.who.int/gb/ebwha/pdf-files/A61/A61-R17-en.pdf
15. WHO/IOM Global Consultation on Migrant Health http://www.iom.int/jahia/ webdav/shared/shared/mainsite/activities/health/promotion/Health-of-Migrants.pdf
16. Lifetime treatment costs of β-thalassaemia major. Karnon J, Zeuner D, Brown J, Ades AE, Wonke B, Modell B, Clin Lab Haem 1999 21 377 385 (Pubitemid 30058771)
17. Screening for sickle cell and thalassaemia in primary care: a cost effectiveness study. Bryan S, Dormandy E, Roberts T, Ades A, Barton P, Juarez-Garcia A, Andronis L, Karnon J, Marteau TM, Br J Gen Pract 2011 10.3399/bjgp11x601325
18. Prevention of β-thalassaemia in Northern Israel-a cost benefit analysis. Koren A, Profeta L, Zalman L, Palmor H, Carina L, Bril Zamir R, Shalev S, Blondheim O, Mediterr J Hematol Infect Dis 2014
19. Resolution WHA59.20. Sickle-cell anaemia. fifty-ninth World Health Assembly Resolution, Geneva, 27 May 2006 (WHA59/2006/REC/1
20. Resolution EB118/R1: Thalassaemia and other Haemoglobinopathies. Executive Resolution board, 118th session, Geneva, 29 May 2006 (EB118/2006/REC/1) 2006
21. Ethnicity Screening Question and Ante-Natal Screening for Sickle Cell and Thalassemia (EQUANS) in England: A randomized controlled trial of two questionnaires. Dyson SM, Culley LA, Gill C, Hubbard S, Kennefick A, Morris P, Rees D, Sutton F, Squire P, Ethn Health 2006 11 2 169 189
22. Activity Report 2011 and Plan of Activities 2012, Thalassaemia International Organisation (TIF) http://www.thalassaemia.org.cy/docs/ 2012%20TIF%20Plan%20Of%20Action.pdf
23. EUCERD Recommendations to the European Commission and the Member States on European Reference Networks for rare diseases http://ec.europa.eu/health/ rare-diseases/european-reference
24. ENERCA Recommendations for Centres of Expertise on Rare Anaemias. A White Book in press